European Investment Fund (EIF)
European Investment Fund...
Gustave Roussy and LXRepair announce a partnership for personalized radiotherapy of cancer
Amolyt Pharma Announces $80 Million Series B Financing led by Sectoral Asset Management and Andera Partners
Amolyt Pharma to Host Key Opinion Leader Webinar and Discuss Results of Phase I Clinical Trial of AZP-3601 on Friday, October 1st at 10:00am ET
Amolyt Pharma Exercises Option to License Optimized Acromegaly Drug Candidate from PeptiDream as it Continues to Build its Rare Endocrine Pipeline.
Theranexus and Beyond Batten Disease Foundation (BBDF) win us Investigational New Drug (IND) approval to start clinical development of BBDF 101